Published on 25 May 2020
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design and world-leaders in their field
Brian McNicoll, University of Dundee
Formed in 2012, Exscientia were the first to automate drug design, surpassing conventional approaches and have since become a leading pharmatech company. The company's founder and CEO is Prof Andrew Hopkins, Chair of Medicinal Informatics in the School of Life Sciences at the University.
Exscientia’s mission is to make safer, more sophisticated drugs available to all - more quickly and efficiently than ever before using AI drug discovery platforms. Exscientia generates their own data and combines the analytical power of AI with the creativity and expertise of their world-class scientists. This allows them to shorten the pre-clinical drug discovery stage by at least three-quarters and, in turn, substantially accelerating the delivery of new treatments to patients worldwide.
The company has won numerous prizes for the founder and the business including Best Emerging Biotech Company at the OBN annual awards in Oct 2017. They have had investment of €15M by Evotec and their strategic collaborations include GlaxoSmithKline and Sanofi.
Diane Taylor, former Director of RIS
Professor Andrew Hopkins, Chief Executive, Exscientia
+44 (0)1382 email@example.com